Myositis Treatment Market Analysis

  • Report ID: 3783
  • Published Date: Nov 20, 2025
  • Report Format: PDF, PPT

Myositis Treatment Market Segmentation:

Type Segment Analysis

The global myositis treatment market is segmented and analyzed for demand and supply by type into dermatomyositis, inclusion-body myositis, juvenile myositis, polymyositis, and toxic myositis. Out of these types of myositis, the polymyositis segment is estimated to gain the largest market share of about 28% in the year 2035. The major factor that is attributed to segment growth is the rising prevalence of polymyositis among the global population. The report published by the National Library of Medicine stated that the estimated prevalence of polymyositis is 5 to 22 per 100,000 persons, while incidence is around 19 per million at risk per year globally. Also, polymyositis is considered to be the most occurring type of myositis among the global population which is anticipated to create favorable opportunities for market growth. Also, polymyositis is common in individuals who do not seek timely medical health checkups and can cause disability if not cured with timely intervention, thus expanding market size. Furthermore, the presence of polymyositis in a number of clinical pipelines of key market players is also anticipated to fuel market growth in the forecast period.

End-user Segment Analysis

The global myositis treatment market is also segmented and analyzed for demand and supply by end-user into hospitals, home care, specialty clinics, and others. Amongst these segments, the hospital segment is expected to garner a significant share of around 42% in the year 2035 with a significant CAGR value. The availability of hospitals in every region of the world along with the presence of advanced therapy medicinal products for the treatment of myositis is considered to be a major factor in the expansion of the segment. For instance, there were over 8,000 hospitals in Japan as of 2020. Korea, by contrast, had about 4,000 hospitals. In addition, there were more than 6000 hospitals in the United States. Also, the rising preference of hospitals for receiving treatment by the population owing to the accessibility of trained medical staff and professionals along with the rising investments to enhance hospital infrastructure and escalation in patient inflow for treatments are other factors that are attributed to positively contribute to segment growth.

Our in-depth analysis of the global market includes the following segments:

             By Type

  • Dermatomyositis
  • Inclusion-Body Myositis
  • Juvenile Myositis
  • Polymyositis
  • Toxic Myositis

             By Treatment

  • Corticosteroids
  • Immunosuppressant Drug
  • Physical Therapy
  • Others

             By End User

  • Hospital
  • Homecare
  • Specialty Clinics
  • Others

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of myositis treatment is assessed at USD 753.47 million.

The global myositis treatment market size was valued at around USD 725.4 million in 2025 and is projected to grow at a CAGR of more than 4.3%, reaching USD 1.11 billion revenue by 2035.

By 2035, North America is poised to command a 37% share of the myositis treatment market during 2026-2035, supported by the escalating burden of musculoskeletal disorders.

Key players in the market include Baxter International, Inc., Eli Lilly and Company, Novartis AG, Sanofi-aventis Groupe, Abbott Laboratories, Johnson & Johnson Services, Inc., Merck & Co., Inc., Siemens Healthcare GmbH, Pfizer Inc., Becton, Dickinson and Company, IBSRELA, Indegene.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos